JP2020509035A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020509035A5 JP2020509035A5 JP2019547371A JP2019547371A JP2020509035A5 JP 2020509035 A5 JP2020509035 A5 JP 2020509035A5 JP 2019547371 A JP2019547371 A JP 2019547371A JP 2019547371 A JP2019547371 A JP 2019547371A JP 2020509035 A5 JP2020509035 A5 JP 2020509035A5
- Authority
- JP
- Japan
- Prior art keywords
- hepatocellular carcinoma
- tumor
- use according
- microvascular
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 17
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 7
- 210000004185 liver Anatomy 0.000 claims 7
- 238000002271 resection Methods 0.000 claims 7
- 230000009545 invasion Effects 0.000 claims 6
- 238000012752 Hepatectomy Methods 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000004083 survival effect Effects 0.000 claims 3
- 241000711549 Hepacivirus C Species 0.000 claims 2
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 1
- 229940124405 anti-hepatitis b virus drug Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 238000001647 drug administration Methods 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 230000009790 vascular invasion Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762465170P | 2017-03-01 | 2017-03-01 | |
| US62/465,170 | 2017-03-01 | ||
| US201762504552P | 2017-05-11 | 2017-05-11 | |
| US62/504,552 | 2017-05-11 | ||
| US201762551770P | 2017-08-29 | 2017-08-29 | |
| US62/551,770 | 2017-08-29 | ||
| PCT/CN2018/077105 WO2018157762A1 (en) | 2017-03-01 | 2018-02-24 | Use of sulfated oligosaccharides in the manufacture of a medicament for treating patients with hepatocellular carcinoma after surgical resection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020509035A JP2020509035A (ja) | 2020-03-26 |
| JP2020509035A5 true JP2020509035A5 (enExample) | 2020-07-09 |
| JP6948080B2 JP6948080B2 (ja) | 2021-10-13 |
Family
ID=63357147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547371A Active JP6948080B2 (ja) | 2017-03-01 | 2018-02-24 | 手術後の肝細胞癌患者を治療するための薬剤の製造における硫酸化オリゴ糖の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10842804B2 (enExample) |
| JP (1) | JP6948080B2 (enExample) |
| KR (1) | KR102265159B1 (enExample) |
| CN (1) | CN110381953A (enExample) |
| TW (1) | TWI693071B (enExample) |
| WO (1) | WO2018157762A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113160911A (zh) * | 2021-02-26 | 2021-07-23 | 杭州臻合健康科技有限公司 | 一种用于术前肝功能耐受性分析的评估系统 |
| CN117476246B (zh) * | 2023-12-25 | 2024-04-19 | 福建大数据一级开发有限公司 | 基于多类型复发事件的患者生存分析方法、介质及装置 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5139797B2 (ja) * | 2004-03-04 | 2013-02-06 | プロジェン ファーマシューティカルズ リミテッド | 硫酸化オリゴ糖誘導体 |
| CN107362168A (zh) * | 2011-06-09 | 2017-11-21 | 基亚生物科技股份有限公司 | 用于抑制肝癌复发、恶化或转移之医药组成物 |
-
2018
- 2018-02-08 US US15/892,343 patent/US10842804B2/en active Active
- 2018-02-24 KR KR1020197028654A patent/KR102265159B1/ko active Active
- 2018-02-24 WO PCT/CN2018/077105 patent/WO2018157762A1/en not_active Ceased
- 2018-02-24 JP JP2019547371A patent/JP6948080B2/ja active Active
- 2018-02-24 CN CN201880014397.6A patent/CN110381953A/zh active Pending
- 2018-02-26 TW TW107106359A patent/TWI693071B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lu et al. | Recent advances in the prevention of hepatocellular carcinoma recurrence | |
| Li et al. | Polymer-and lipid-based nanoparticle therapeutics for the treatment of liver diseases | |
| Zhang et al. | Current targeted therapeutics against COVID-19: based on first-line experience in China | |
| Liu et al. | Exosomes in HBV infection | |
| Hu et al. | Nobiletin, a novel inhibitor, inhibits HBsAg production and hepatitis B virus replication | |
| CN112535685A (zh) | 多聚adp核糖聚合酶抑制剂治疗乙肝病毒相关疾病的新用途 | |
| RU2015114543A (ru) | Способы лечения гепатита с | |
| JP2010520200A5 (enExample) | ||
| JP2008514577A5 (enExample) | ||
| Liu et al. | Effects of antiviral therapy on HBV reactivation and survival in hepatocellular carcinoma patients undergoing hepatic artery infusion chemotherapy | |
| JP2016527202A5 (enExample) | ||
| JP2017514911A5 (enExample) | ||
| JP2018522028A5 (enExample) | ||
| JP2020509035A5 (enExample) | ||
| CN109364079B (zh) | 塔拉帕尼在制备治疗或者预防肝炎病毒相关疾病药物中的用途 | |
| Li et al. | Current trends and advances in antiviral therapy for chronic hepatitis B | |
| CN111417402A (zh) | 充分剂量条件下治疗乙肝病毒相关肝病的药物和方法 | |
| Wei et al. | Perioperative antiviral therapy for chronic hepatitis B-related hepatocellular carcinoma | |
| CN102600129A (zh) | 穿心莲内酯c15位取代衍生物在制备抗丙型肝炎药物中的应用 | |
| EA200900558A1 (ru) | Композиции аполактоферрина и способы их применения в лечении вирусного гепатита с | |
| Jiang et al. | Current status of drug therapy for chronic hepatitis B | |
| RU2013120345A (ru) | Новые способы лечения инфекции, вызванной вирусом гепатита с | |
| JP2016503035A5 (enExample) | ||
| Loustaud‐Ratti et al. | Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir | |
| CN102225069B (zh) | 一种耐药性显著降低的药物组合物及其制备方法和其应用 |